5-Lipoxygenase and atherosclerosis

Current Opinion in Lipidology

Volumn 14, Issue 5, 2003, Pages 447-457

  Mehrabian, Margarete ^a   Allayee, Hooman ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 lipoxygenase; Atherosclerosis; Genetics; Leukotriene biosynthetic pathway

Indexed keywords

APOPTOSIS; ARTERY INTIMA; ARTERY INTIMA PROLIFERATION; ARTERY RUPTURE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL TONE; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; DISEASE COURSE; DISEASE PREDISPOSITION; FOAM CELL; GENE IDENTIFICATION; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LIPID OXIDATION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW;

ANIMALS; APOPTOSIS; ARACHIDONATE 5-LIPOXYGENASE; ARTERIOSCLEROSIS; CHEMOTAXIS; HUMANS; HYPERPLASIA; INFLAMMATION; LEUKOTRIENES; MACROPHAGES; MONOCYTES; TUNICA INTIMA;

SIGANUS;

EID: 0142093151     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200310000-00005     Document Type: Review

References (95)

1. Peters-Golden M. Cell biology of the 5-lipoxygenase pathway. Am J Respir Crit Care Med 1998; 157:S227-S232.
2. Leff AR. Regulation of leukotrienes in the management of asthma: biology and clinical therapy. Annu Rev Med 2001; 52:1-14.
3. Coffey M, Peters-Golden M. Extending the understanding of leukotrienes in asthma. Curr Opin Allergy Clin Immunol 2003; 3:57-63. This article reviews recent findings in the regulation of 5LO and cysLTs and their association with cytokines.
4. Goulet JL, Griffiths RC, Ruiz P, et al. Deficiency of 5-lipoxygenase abolishes sex-related survival differences in MRL-lpr/lpr mice. J Immunol 1999; 163:359-366.
5. Boyce BF, Hughes DE, Wright KR, et al. Recent advances in bone biology provide insight into the pathogenesis of bone diseases. Lab Invest 1999; 79:83-94.
6. Goulet JL, Griffiths RC, Ruiz P, et al. Deficiency of 5-lipoxygenase accelerates renal allograft rejection in mice. J Immunol 2001; 167:6631-6636.
7. Mehrabian M, Allayee H, Wong J, et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 2002; 91:120-126. Using a positional candidate approach, this study demonstrates that 5LO protects against aortic lesion formation in two mouse models, even in the presence of elevated cholesterol levels. It was also shown that 5LO is expressed in the cells of atherosclerotic lesions, particularly in macrophage-rich regions.
8. Spanbroek R, Grabner R, Lotzer K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 2003; 100:1238-1243. This study demonstrates that 5LO is expressed in human atherosclerotic lesions and progressively increases with lesion severity, which is consistent with observations in mice.
9. Lusis AJ. Atherosclerosis. Nature 2000; 407:233-241.
10. Mehrabian M, Wen PZ, Fisler J, et al. Genetic loci controlling body fat, lipoprotein metabolism, and insulin levels in a multifactorial mouse model. J Clin Invest 1998; 101:2485-2496.
11. Mehrabian M, Castellani LW, Wen PZ, et al. Genetic control of HDL levels and composition in an interspecific mouse cross (CAST/Ei x C57BL/6J). J Lipid Res 2000; 41:1936-1946.
12. Villa-Colinayo V, Shi W, Araujo J, Lusis AJ. Genetics of atherosclerosis: the search for genes acting at the level of the vessel wall. Curr Atheroscler Rep 2000; 2:380-389.
13. Silver LM. Mouse genetics: concepts and applications. New York: Oxford University Press; 1995.
14. Mehrabian M, Wong J, Wang X, et al. Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia. Circ Res 2001; 89:125-130.
15. Cushing SD, Berliner JA, Valente AJ, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990; 87:5134-5138.
16. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell 2001; 104:503-516.
17. Kuhn H, Anton M, Gerth C, Habenicht A. Amino acid differences in the deduced 5-lipoxygenase sequence of CAST Atherosclerosis-resistance mice confer impaired activity when introduced into the human ortholog. Arterioscler Thromb Vasc Biol 2003; 23:1072-1076. This study demonstrated that substituting the corresponding amino acid from CON6 mice into the human 5LO protein significantly reduced the activity of the enzyme. These results support the observation that CON6 mice have very low levels of 5LO and LTs.
18. Chen XS, Sheller JR, Johnson EN, Funk CD. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 1994; 372:179-182.
19. Funk CD, Hoshiko S, Matsumoto T, et al. Characterization of the human 5-lipoxygenase gene. Proc Natl Acad Sci USA 1989; 86:2587-2591.
20. Silverman ES, Drazen JM. The biology of 5-lipoxygenase: function, structure, and regulatory mechanisms. Proc Assoc Am Physicians 1999; 111:525-536.
21. Drazen JM, Yandava CN, Dube L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22:168-170.
22. O'Leary DH, Polak JF. Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol 2002; 90:18L-21L.
23. Allayee H, Dwyer JH, Fan J, et al. A promoter polymorphism of 5-Lipoxygenase is associated with carotid atherosclerosis in the human population. Am J Hum Genet 2002; 71:S435.
24. Peters-Golden M, McNish RW. Redistribution of 5-lipoxygenase and cytosolic phospholipase A2 to the nuclear fraction upon macrophage activation. Biochem Biophys Res Commun 1993; 196:147-153.
25. Peters-Golden M, Brock TG. Intracellular compartmentalization of leukotriene biosynthesis. Am J Respir Crit Care Med 2000; 161:336-340.
26. Samuelsson B, Haeggstrom JZ, Wetterholm A. Leukotriene biosynthesis. Ann N Y Acad Sci 1991; 629:89-99.
27. Henderson Jr WR. The role of leukotrienes in inflammation. Ann Intern Med 1994; 121:684-697.
28. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990; 323:645-655.
29. Byrum RS, Goulet JL, Snouwaert JN, et al. Determination of the contribution of cysteinyl leukotrienes and leukotriene B4 in acute inflammatory responses using 5-lipoxygenase- and leukotriene A4 hydrolase-deficient mice. J Immunol 1999; 163:6810-6819.
30. Bigby TD. The yin and the yang of 5-lipoxygenase pathway activation. Mol Pharmacol 2002; 62:200-202.
31. Dahlen SE, Bjork J, Hedqvist P, et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci USA 1981; 78:3887-3891.
32. Smith, WL, Borgeat P, and Fitzpatrick FA. The eicosanoids: cyclooxygenase, lipoxygenase, and epoxygenase pathways. In: Vance DE, and Vance J, editors. Biochemistry of Lipids, Lipoproteins and Membranes, Amsterdam: Elsevier Science, 1991, pp. 297-325.
33. Goulet JL, Snouwaert JN, Latour AM, et al. Altered inflammatory responses in leukotriene-deficient mice. Proc Natl Acad Sci USA 1994; 91:12852-12856.
34. Fabre JE, Goulet JL, Riche E, et al. Transcellular biosynthesis contributes to the production of leukotrienes during inflammatory responses in vivo. J Clin Invest 2002; 109:1373-1380.
35. Uhl J, Klan N, Rose M, et al. The 5-lipoxygenase promoter is regulated by DNA methylation. J Biol Chem 2002; 277:4374-4379. This study demonstrates that expression of the 5LO gene can be regulated by the methylation of its promoter. For example, 5LO-negative cell lines expressed 5LO when incubated with a demethylating agent.
36. 4 pathway to inflammation control. Nature 1996; 384:39-43.
37. Lee H, Shi W, Tontonoz P, et al. Role for peroxisome proliferator- activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res 2000; 87:516-521.
38. Hankin JA, Jones DN, Murphy RC. Covalent binding of leukotriene A4 to DNA and RNA. Chem Res Toxicol 2003; 16:551-561.
39. Navab M, Berliner JA, Watson AD, et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996; 16:831-842.
40. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21:1876-1890.
41. Stockton RA, Jacobson BS. Modulation of cell-substrate adhesion by arachidonic acid: lipoxygenase regulates cell spreading and ERK1/2-inducible cyclooxygenase regulates cell migration in NIH-3T3 fibroblasts. Mol Biol Cell 2001; 12:1937-1956.
42. Gerrity RG. The role of the monocyte in atherogenesis: I. Transition of bloodborne monocytes into foam cells in fatty lesions. Am J Pathol 1981; 103:181-190.
43. Berliner JA, Territo MC, Sevanian A, et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 1990; 85:1260-1266.
44. Leitinger N, Tyner TR, Oslund L, et al. Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils. Proc Natl Acad Sci USA 1999; 96:12010-12015.
45. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-126.
46. Allen S, Dashwood M, Morrison K, Yacoub M. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation 1998; 97:2406-2413.
47. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868-874.
48. Fair A, Pritchard KA Jr. Oxidized low density lipoprotein increases U937 cell 5-lipoxygenase activity: induction of 5-lipoxygenase activating protein. Biochem Biophys Res Commun 1994; 201:1014-1020.
49. Lee S, Felts KA, Parry GC, et al. Inhibition of 5-lipoxygenase blocks IL-1 beta-induced vascular adhesion molecule-1 gene expression in human endothelial cells. J Immunol 1997; 158:3401-3407.
50. Woods JW, Coffey MJ, Brock TG, et al. 5-Lipoxygenase is located in the euchromatin of the nucleus in resting human alveolar macrophages and translocates to the nuclear envelope upon cell activation. J Clin Invest 1995; 95:2035-2046.
51. Sozzani S, Zhou D, Locati M, et al. Stimulating properties of 5-oxoeicosanoids for human monocytes: synergism with monocyte chemotactic protein-1 and -3. J Immunol 1996; 157:4664-4671.
52. Rollins BJ. JE/MCP-1: an early-response gene encodes a monocyte-specific cytokine. Cancer Cells 1991; 3:517-524.
53. Aiello RJ, Bourassa PA, Lindsey S, et al. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 2002; 22:443-449. This important study demonstrates that pharmacologic antagonism of the BLTR sigificantly reduced atherosclerosis in hyperlipidemic mice, indicating that the proatherogenic role of LTs is modulated through its G-coupled protein receptor.
54. Rosenfeld ME. Leukocyte recruitment into developing atherosclerotic lesions: the complex interaction between multiple molecules keeps getting more complex. Arterioscler Thromb Vasc Biol 2002; 22:361-363.
55. Matsukawa A, Hogaboam CM, Lukacs NW, et al. Endogenous monocyte chemoattractant protein-1 (MCP-1) protects mice in a model of acute septic peritonitis: cross-talk between MCP-1 and leukotriene B4. J Immunol 1999; 163:6148-6154.
56. Metcalf D. The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells. Nature 1989; 339:27-30.
57. Rosenfeld ME, Yla-Herttuala S, Lipton BA, et al. Macrophage colony-stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humans. Am J Pathol 1992; 140:291-300.
58. Rajavashisth T, Qiao JH, Tripathi S, et al. Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest 1998; 101:2702-2710.
59. Krump E, Borgeat P. Kinetics of 5-lipoxygenase activation, arachidonic acid release, and leukotriene synthesis in human neutrophils: effects of granulocyte-macrophage colony-stimulating factor. Biochim Biophys Acta 1994; 1213:135-139.
60. Stankova J, Rola-Pleszczynski M, Dubois CM. Granulocyte-macrophage colony-stimulating factor increases 5-lipoxygenase gene transcription and protein expression in human neutrophils. Blood 1995; 85:3719-3726.
61. Brock TG, McNish RW, Coffey MJ, et al. Effects of granulocyte-macrophage colony-stimulating factor on eicosanoid production by mononuclear phagocytes. J Immunol 1996; 156:2522-2527.
62. Romano M, Catalano A, Nutini M, et al. 5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. FASEB J 2001; 15:2326-2336.
63. Celletti FL, Waugh JM, Amabile PG, et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 7:425-429.
64. Schwartz SM. The intima: a new soil. Circ Res 1999; 85:877-879.
65. O'Brien ER, Urieli-Shoval S, Garvin MR, et al. Replication in restenotic atherectomy tissue. Atherosclerosis 2000; 152:117-126.
66. Rectenwald JE, Moldawer LL, Huber TS, et al. Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation 2000; 102:1697-1702.
67. Cartaruzza M, Schafer K, Hecker M. Cytokine-induced down-regulation of zfm1/splicing factor-1 promotes smooth muscle cell proliferation. J Biol Chem 2002; 277:6582-6589.
68. Kirii H, Niwa T, Yamada Y, et al. Lack of interleukin-1β decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23:656-660.
69. Rola-Pleszczynski M, Lemaire I. Leukotrienes augment interteukin 1 production by human monocytes. J Immunol 1985; 135:3958-3961.
70. Devaraj S, Jialal I. Alpha-tocopherol decreases interleukin-1 beta release from activated human monocytes by inhibition of 5-lipoxygenase. Arterioscler Thromb Vasc Biol 1999; 19:11215-1133.
71. Azzi A, Breyer I, Feher M, et al. Specific cellular responses to alpha-tocopherol. J Nutr 2000; 130:1649-1652.
72. O'Neill LA, Greene C. Signal transduction pathways activated by the IL-1 receptor family: ancient signaling machinery in mammals, insects, and plants. J Leukoc Biol 1998; 63:650-657.
73. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94:2493-2503.
74. Taylor PM, Woodfield RJ, Hodgkin MN, et al. Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway. Oncogene 2002; 21:5765-5772. This study implicates 5LO in the degradation of the fibrotic caps of lesions, leading to plaque destabilization and rupture.
75. He W, Pelletier JP, Martel-Pelletier J, et al. Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines. J Rheumatol 2002; 29:546-553.
76. Negoro N, Kanayama Y, Haraguchi M, et al. Blood pressure regulates platelet-derived growth factor A-chain gene expression in vascular smooth muscle cells in vivo. An autocrine mechanism promoting hypertensive vascular hypertrophy. J Clin Invest 1995; 95:1140-1150.
77. Hardy G, Stanke-Labesque F, Peoc'h M, et al. Cysteinyl leukotrienes modulate angiotensin II constrictor effects on aortas from streptozotocin- induced diabetic rats. Arterioscler Thromb Vasc Biol 2001; 21:1751-1758.
78. Lawson DL, Mehta JL, Mehta P, Nichols WW. Endothelium-dependent relaxation of rat aortic rings by leukotriene D4: importance of the magnitude of preload. Eicosanoids 1989; 2:175-181.
79. Ishizaka N, Nakao A, Ohishi N, et al. Increased leukotriene A(4) hydrolase expression in the heart of angiotensin II-induced hypertensive rat. FEBS Lett 1999; 463:155-159.
80. Zukowska-Grojec Z, Bayorh MA, Kopin IJ, Feuerstein G. Overall and regional hemodynamic effects of leukotriene D4 in spontaneously hypertensive rats. Hypertension 1985; 7:507-513.
81. Voelkel NF, Tuder RM, Wade K, et al. Inhibition of 5-lipoxygenase- activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. J Clin Invest 1996; 97:2491-2498.
82. Steele VE, Holmes CA, Hawk ET, et al. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1999; 8:467-483.
83. La E, Kern JC, Atarod EB, Kehrer JP. Fatty acid release and oxidation are factors in lipoxygenase inhibitor-induced apoptosis. Toxicol Lett 2003; 138:193-203.
84. Hebert MJ, Takano T, Holthofer H, Brady HR. Sequential morphologic events during apoptosis of human neutrophils. Modulation by lipoxygenase- derived eicosanoids. J Immunol 1996; 157:3105-3115.
85. Ghosh J, Myers CE. Central role of arachidonate 5-lipoxygenase in the regulation of cell growth and apoptosis in human prostate cancer cells. Adv Exp Med Biol 1999; 469:577-582.
86. Avis I, Hong SH, Martinez A, et al. Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J 2001; 15:2007-2009.
87. Maccarrone M, Battista N, Meloni M, et al. Creating conditions similar to those that occur during exposure of cells to microgravity induces apoptosis in human lymphocytes by 5-lipoxygenase-mediated mitochondrial uncoupling and cytochrome c release. J Leukoc Biol 2003; 73:472-481.
88. Maccarrone M, Taccone-Gallucci M, Finazzi-Agro A. 5-Lipoxygenase- mediated mitochondrial damage and apoptosis of mononuclear cells in ESRD patients. Kidney Int Suppl 2003; 84:33-36.
89. Montero A, Nassar GM, Uda S, et al. Reciprocal regulation of LTA(4) hydrolase expression in human monocytes by gamma-interferon and interleukins 4 and 13: potential relevance to leukotriene regulation in glomerular disease. Exp Nephrol 2000; 8:258-265.
90. Dugas N, Dugas B, Kolb JP, et al. Role of leukotriene B4 in the interleukin-4-induced human mononuclear phagocyte activation. Immunology 1996; 88:384-388.
91. Zaitsu M, Hamasaki Y, Matsuo M, et al. New induction of leukotriene A(4) hydrolase by interleukin-4 and interleukin-13 in human polymorphonuclear leukocytes. Blood 2000; 96:601-609.
92. Morita H, Takeda K, Yagita H, Okumura K. Immunosuppressive effect of leukotriene B(4) receptor antagonist in vitro. Biochem Biophys Res Commun 1999; 264:321-326.
93. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-252.
94. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91:281-291.
95. Spanbroek R, Hildner M, Steinhilber D, et al. 5-lipoxygenase expression in dendritic cells generated from CD34(+) hematopoietic progenitors and in lymphoid organs. Blood 2000; 96:3857-3865.